HEADER BLOOD CLOTTING 26-JUN-08 2VWO TITLE AMINOPYRROLIDINE FACTOR XA INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: ACTIVATED FACTOR XA HEAVY CHAIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: PEPTIDASE S1 DOMAIN, RESIDUES 235-475; COMPND 5 EC: 3.4.21.6; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: FACTOR X LIGHT CHAIN; COMPND 10 CHAIN: L; COMPND 11 FRAGMENT: EGF2, RESIDUES 126-180; COMPND 12 EC: 3.4.21.6; COMPND 13 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 MOL_ID: 2; SOURCE 8 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 9 ORGANISM_COMMON: HUMAN; SOURCE 10 ORGANISM_TAXID: 9606; SOURCE 11 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 12 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS HYDROLASE, CATION, PLASMA, CALCIUM, ZYMOGEN, PROTEASE, INHIBITOR, KEYWDS 2 POLYMORPHISM, GLYCOPROTEIN, GAMMA-CARBOXYGLUTAMIC ACID, BLOOD KEYWDS 3 CLOTTING, COAGULATION FACTOR, HYDROXYLATION, SERINE PROTEASE, EGF- KEYWDS 4 LIKE DOMAIN, CLEAVAGE ON PAIR OF BASIC RESIDUES EXPDTA X-RAY DIFFRACTION AUTHOR K.GROEBKE-ZBINDEN,D.W.BANNER,J.M.BENZ,F.BLASCO,G.DECORET,J.HIMBER, AUTHOR 2 B.KUHN,N.PANDAY,F.RICKLIN,P.RISCH,D.SCHLATTER,M.STAHL,R.UNGER,W.HAAP REVDAT 2 13-DEC-23 2VWO 1 REMARK LINK REVDAT 1 07-JUL-09 2VWO 0 JRNL AUTH K.G.ZBINDEN,L.ANSELM,D.W.BANNER,J.M.BENZ,F.BLASCO,G.DECORET, JRNL AUTH 2 J.HIMBER,B.KUHN,N.PANDAY,F.RICKLIN,P.RISCH,D.SCHLATTER, JRNL AUTH 3 M.STAHL,S.THOMI,R.UNGER,W.HAAP JRNL TITL DESIGN OF NOVEL AMINOPYRROLIDINE FACTOR XA INHIBITORS FROM A JRNL TITL 2 SCREENING HIT. JRNL REF EUR.J.MED.CHEM. V. 44 2787 2009 JRNL REFN ISSN 0223-5234 JRNL PMID 19200624 JRNL DOI 10.1016/J.EJMECH.2008.12.025 REMARK 2 REMARK 2 RESOLUTION. 1.60 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.4.0077 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.60 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 47.09 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 3 NUMBER OF REFLECTIONS : 34963 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.196 REMARK 3 R VALUE (WORKING SET) : 0.194 REMARK 3 FREE R VALUE : 0.228 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1839 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.60 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.64 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2499 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2320 REMARK 3 BIN FREE R VALUE SET COUNT : 132 REMARK 3 BIN FREE R VALUE : 0.2450 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2156 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 39 REMARK 3 SOLVENT ATOMS : 221 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 23.85 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.14000 REMARK 3 B22 (A**2) : 0.14000 REMARK 3 B33 (A**2) : -0.28000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.099 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.099 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.061 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 1.712 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.955 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.937 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2304 ; 0.010 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 3108 ; 1.378 ; 1.967 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 284 ; 5.686 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 102 ;34.647 ;23.922 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 396 ;12.306 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 15 ;12.608 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 330 ; 0.090 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 1750 ; 0.005 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1406 ; 0.784 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2253 ; 1.407 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 898 ; 1.893 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 855 ; 3.033 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2VWO COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 26-JUN-08. REMARK 100 THE DEPOSITION ID IS D_1290036708. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 21-FEB-05 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SLS REMARK 200 BEAMLINE : X06SA REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9787 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XDS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 36802 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.600 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 200 DATA REDUNDANCY : 6.400 REMARK 200 R MERGE (I) : 0.05000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 19.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.60 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.70 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.0 REMARK 200 DATA REDUNDANCY IN SHELL : 6.40 REMARK 200 R MERGE FOR SHELL (I) : 0.37000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 5.420 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: PDB ENTRY 2VVC REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 42.20 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.14 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 43 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z+1/2 REMARK 290 3555 -Y+1/2,X+1/2,Z+3/4 REMARK 290 4555 Y+1/2,-X+1/2,Z+1/4 REMARK 290 5555 -X+1/2,Y+1/2,-Z+3/4 REMARK 290 6555 X+1/2,-Y+1/2,-Z+1/4 REMARK 290 7555 Y,X,-Z REMARK 290 8555 -Y,-X,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 24.70250 REMARK 290 SMTRY1 3 0.000000 -1.000000 0.000000 52.64050 REMARK 290 SMTRY2 3 1.000000 0.000000 0.000000 52.64050 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 37.05375 REMARK 290 SMTRY1 4 0.000000 1.000000 0.000000 52.64050 REMARK 290 SMTRY2 4 -1.000000 0.000000 0.000000 52.64050 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 12.35125 REMARK 290 SMTRY1 5 -1.000000 0.000000 0.000000 52.64050 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 52.64050 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 37.05375 REMARK 290 SMTRY1 6 1.000000 0.000000 0.000000 52.64050 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 52.64050 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 12.35125 REMARK 290 SMTRY1 7 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY2 7 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 24.70250 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 TOTAL BURIED SURFACE AREA: 1960 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 15490 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -12.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, L REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: L REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 NA NA A1249 LIES ON A SPECIAL POSITION. REMARK 375 HOH A2059 LIES ON A SPECIAL POSITION. REMARK 400 REMARK 400 COMPOUND REMARK 400 ENGINEERED RESIDUE IN CHAIN A, ARG 372 TO GLU REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 246 REMARK 465 LEU A 247 REMARK 465 PRO A 248 REMARK 465 LYS A 249 REMARK 465 ALA A 250 REMARK 465 LYS A 251 REMARK 465 ARG L 86 REMARK 465 LYS L 87 REMARK 465 HIS L 101 REMARK 465 GLU L 102 REMARK 465 GLU L 103 REMARK 465 GLN L 104 REMARK 465 ASN L 105 REMARK 465 SER L 106 REMARK 465 ASP L 119 REMARK 465 ASN L 120 REMARK 465 GLY L 121 REMARK 465 ARG L 140 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG A 245 CA C O CB CG CD NE REMARK 470 ARG A 245 CZ NH1 NH2 REMARK 470 ARG L 139 CA C O CB CG CD NE REMARK 470 ARG L 139 CZ NH1 NH2 REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 ASN A 92 CG OD1 ND2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 2019 O HOH A 2065 2.03 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 TYR A 99 14.33 56.81 REMARK 500 ASP L 95 -4.35 70.75 REMARK 500 GLN L 98 -104.51 -129.11 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2016 DISTANCE = 6.37 ANGSTROMS REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 NA A1249 NA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 GLN A 20 OE1 REMARK 620 2 GLN A 20 OE1 101.8 REMARK 620 3 HOH A2010 O 94.1 162.0 REMARK 620 4 HOH A2010 O 163.0 92.8 73.0 REMARK 620 5 HOH A2011 O 110.5 84.2 82.4 79.4 REMARK 620 6 HOH A2011 O 85.0 109.5 79.9 81.9 157.3 REMARK 620 N 1 2 3 4 5 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 CA A1246 CA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASP A 70 OD1 REMARK 620 2 ASN A 72 O 87.5 REMARK 620 3 GLN A 75 O 166.2 86.8 REMARK 620 4 GLU A 77 OE2 86.7 87.6 80.5 REMARK 620 5 GLU A 80 OE2 93.5 171.7 90.4 84.2 REMARK 620 6 HOH A2060 O 91.4 92.9 101.4 178.0 95.3 REMARK 620 N 1 2 3 4 5 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 NA A1247 NA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 TYR A 185 O REMARK 620 2 ASP A 185A O 80.9 REMARK 620 3 ARG A 222 O 166.5 86.3 REMARK 620 4 HOH A2163 O 96.1 84.1 86.5 REMARK 620 N 1 2 3 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 NA A1248 NA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 HOH A2038 O REMARK 620 2 HOH A2039 O 86.0 REMARK 620 3 HOH A2103 O 96.5 177.0 REMARK 620 4 HOH A2105 O 89.2 93.8 84.5 REMARK 620 5 HOH A2106 O 177.4 96.0 81.6 92.3 REMARK 620 6 HOH A2131 O 88.8 81.6 100.2 175.1 89.8 REMARK 620 N 1 2 3 4 5 REMARK 700 REMARK 700 SHEET REMARK 700 DETERMINATION METHOD: DSSP REMARK 700 THE SHEETS PRESENTED AS "AA" IN EACH CHAIN ON SHEET RECORDS REMARK 700 BELOW IS ACTUALLY AN 8-STRANDED BARREL THIS IS REPRESENTED BY REMARK 700 A 9-STRANDED SHEET IN WHICH THE FIRST AND LAST STRANDS REMARK 700 ARE IDENTICAL. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE LZG A 1245 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CA A 1246 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NA A 1247 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NA A 1248 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NA A 1249 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 1250 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 1251 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1WU1 RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 4 -[(5-CHLOROINDOL-2-YL) REMARK 900 SULFONYL]-2-(2- METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL)PYRIMIDIN -2-YL] REMARK 900 CARBONYL]PIPERAZINE REMARK 900 RELATED ID: 2J34 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2BQ7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 43 REMARK 900 RELATED ID: 2W3K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4 ,4-DISUBSTITUTED REMARK 900 PYRROLIDINE-1,2- DICARBOXAMIDE INHIBITOR 1 REMARK 900 RELATED ID: 1XKA RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S) -(3'- REMARK 900 AMIDINO-3- BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID REMARK 900 RELATED ID: 1NFW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR209685 REMARK 900 RELATED ID: 2GD4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE ANTITHROMBIN-S195A FACTOR XA- REMARK 900 PENTASACCHARIDE COMPLEX REMARK 900 RELATED ID: 2VVV RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE-RELATED TRIAZOLE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1MSX RELATED DB: PDB REMARK 900 HUMAN FACTOR XA COMPLEXED WITH 2-[3-(15N- AMINO-15N-IMINO-13C- REMARK 900 METHYL)PHENOXY]-6-[3 -(15N-AMINO-13C-METHYL)PHENOXY]-3,5- DIFLUORO- REMARK 900 4-METHYLPYRIDINE (ZK-806299), BINDING MODELFROM DOUBLE REDOR NMR REMARK 900 AND MD SIMULATIONS. REMARK 900 RELATED ID: 1LPG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79. REMARK 900 RELATED ID: 2VVU RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1P0S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BLOOD COAGULATION FACTOR XA IN COMPLEXWITH REMARK 900 ECOTIN M84R REMARK 900 RELATED ID: 2G00 RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 3 -(6-(2'-((DIMETHYLAMINO) REMARK 900 METHYL)-4-BIPHENYLYL )-7-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7- REMARK 900 TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-1- YL)BENZAMIDE REMARK 900 RELATED ID: 1MQ6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO -2-[[(5-CHLORO-2- REMARK 900 PYRIDINYL)AMINO]CARBONYL ]-6-METHOXYPHENYL]-4-[[(4,5-DIHYDRO-2- REMARK 900 OXAZOLYL)METHYLAMINO]METHYL]-2- THIOPHENECARBOXAMIDE COMPLEXED WITH REMARK 900 HUMAN FACTOR XA REMARK 900 RELATED ID: 1XKB RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S) -(3'- REMARK 900 AMIDINO-3- BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID REMARK 900 RELATED ID: 1IQE RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55590 REMARK 900 RELATED ID: 1G2M RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2VH0 RELATED DB: PDB REMARK 900 STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS:BIARYL REMARK 900 PYRROLIDIN-2- ONES INCORPORATING BASIC HETEROCYCLIC MOTIFS REMARK 900 RELATED ID: 1NFY RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR200095 REMARK 900 RELATED ID: 2UWL RELATED DB: PDB REMARK 900 SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND REMARK 900 FACTOR XA REMARK 900 RELATED ID: 2BOK RELATED DB: PDB REMARK 900 FACTOR XA - CATION REMARK 900 RELATED ID: 1HCG RELATED DB: PDB REMARK 900 BLOOD COAGULATION FACTOR XA REMARK 900 RELATED ID: 1LPZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41. REMARK 900 RELATED ID: 2W3I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4 ,4-DISUBSTITUTED REMARK 900 PYRROLIDINE-1,2- DICARBOXAMIDE INHIBITOR 2 REMARK 900 RELATED ID: 1Z6E RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA COMPLEXED TO RAZAXABAN REMARK 900 RELATED ID: 2JKH RELATED DB: PDB REMARK 900 FACTOR XA - CATION INHIBITOR COMPLEX REMARK 900 RELATED ID: 2UWP RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1G2L RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1NFU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR132747 REMARK 900 RELATED ID: 2BQ6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 21 REMARK 900 RELATED ID: 1FAX RELATED DB: PDB REMARK 900 COAGULATION FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1IQF RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55165 REMARK 900 RELATED ID: 1NL8 RELATED DB: PDB REMARK 900 THEORETICAL MODEL OF THE TISSUE FACTOR/ FACTOR VIIA/FACTORXA COMPLEX REMARK 900 RELATED ID: 1IQG RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55159 REMARK 900 RELATED ID: 1IQH RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55143 REMARK 900 RELATED ID: 1LQD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45. REMARK 900 RELATED ID: 2UWO RELATED DB: PDB REMARK 900 SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND REMARK 900 FACTOR XA REMARK 900 RELATED ID: 1C5M RELATED DB: PDB REMARK 900 STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, REMARK 900 SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR REMARK 900 RELATED ID: 1IOE RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55532 REMARK 900 RELATED ID: 1F0S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR208707 REMARK 900 RELATED ID: 1F0R RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR208815 REMARK 900 RELATED ID: 2BMG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 50 REMARK 900 RELATED ID: 1MQ5 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO -2-[[(4-CHLOROPHENYL) REMARK 900 AMINO]CARBONYL]PHENYL]- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-2- REMARK 900 THIOPHENECARBOXAMIDE COMPLEXED WITHHUMAN FACTOR XA REMARK 900 RELATED ID: 1IQN RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55192 REMARK 900 RELATED ID: 2BQW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45 REMARK 900 RELATED ID: 1IQM RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M54471 REMARK 900 RELATED ID: 1EZQ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR128515 REMARK 900 RELATED ID: 2VWL RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 2VH6 RELATED DB: PDB REMARK 900 STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: REMARK 900 PYRROLIDIN-2-ONES WITH BIARYL P4 MOTIFS REMARK 900 RELATED ID: 1FJS RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031)COMPLEXED REMARK 900 WITH FACTOR XA REMARK 900 RELATED ID: 1LPK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125. REMARK 900 RELATED ID: 2J4I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1NFX RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR208944 REMARK 900 RELATED ID: 2VWN RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 2J94 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1IQJ RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55124 REMARK 900 RELATED ID: 2CJI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2J95 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2BOH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 1 REMARK 900 RELATED ID: 2J38 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2W26 RELATED DB: PDB REMARK 900 FATOR XA IN COMPLEX WITH BAY59-7939 REMARK 900 RELATED ID: 2VVC RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1IQI RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55125 REMARK 900 RELATED ID: 2VWM RELATED DB: PDB REMARK 900 AMINOPYRROLIDINE FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1KYE RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH (R)-2-(3- ADAMANTAN-1-YL-UREIDO)-3-(3- REMARK 900 CARBAMIMIDOYL- PHENYL)-N-PHENETHYL-PROPIONAMIDE REMARK 900 RELATED ID: 1IQK RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55113 REMARK 900 RELATED ID: 1V3X RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 1 -[6-METHYL-4,5,6,7- REMARK 900 TETRAHYDROTHIAZOLO(5, 4-C)PYRIDIN-2-YL] CARBONYL-2-CARBAMOYL-4 -(6- REMARK 900 CHLORONAPHTH-2-YLSULPHONYL)PIPERAZINE REMARK 900 RELATED ID: 2FZZ RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 1 -(3-AMINO-1,2- REMARK 900 BENZISOXAZOL-5-YL)-6-(2 '-(((3R)-3-HYDROXY-1-PYRROLIDINYL)METHYL)-4 REMARK 900 -BIPHENYLYL)-3-(TRIFLUOROMETHYL)-1,4,5,6- TETRAHYDRO-7H-PYRAZOLO[3, REMARK 900 4-C]PYRIDIN-7- ONE REMARK 900 RELATED ID: 2J2U RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1KSN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 FXV673 REMARK 900 RELATED ID: 1IQL RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M54476 REMARK 999 REMARK 999 SEQUENCE REMARK 999 ARG-GLU MUTANT.THE RESIDUE NUMBERING IN THE CATALYTIC REMARK 999 DOMAIN FOLLOWS THAT OF CHYMOTRYPSINOGEN DBREF 2VWO A 16 251 UNP P00742 FA10_HUMAN 235 475 DBREF 2VWO L 86 140 UNP P00742 FA10_HUMAN 126 180 SEQADV 2VWO GLU A 150 UNP P00742 ARG 372 ENGINEERED MUTATION SEQRES 1 A 241 ILE VAL GLY GLY GLN GLU CYS LYS ASP GLY GLU CYS PRO SEQRES 2 A 241 TRP GLN ALA LEU LEU ILE ASN GLU GLU ASN GLU GLY PHE SEQRES 3 A 241 CYS GLY GLY THR ILE LEU SER GLU PHE TYR ILE LEU THR SEQRES 4 A 241 ALA ALA HIS CYS LEU TYR GLN ALA LYS ARG PHE LYS VAL SEQRES 5 A 241 ARG VAL GLY ASP ARG ASN THR GLU GLN GLU GLU GLY GLY SEQRES 6 A 241 GLU ALA VAL HIS GLU VAL GLU VAL VAL ILE LYS HIS ASN SEQRES 7 A 241 ARG PHE THR LYS GLU THR TYR ASP PHE ASP ILE ALA VAL SEQRES 8 A 241 LEU ARG LEU LYS THR PRO ILE THR PHE ARG MET ASN VAL SEQRES 9 A 241 ALA PRO ALA CYS LEU PRO GLU ARG ASP TRP ALA GLU SER SEQRES 10 A 241 THR LEU MET THR GLN LYS THR GLY ILE VAL SER GLY PHE SEQRES 11 A 241 GLY ARG THR HIS GLU LYS GLY GLU GLN SER THR ARG LEU SEQRES 12 A 241 LYS MET LEU GLU VAL PRO TYR VAL ASP ARG ASN SER CYS SEQRES 13 A 241 LYS LEU SER SER SER PHE ILE ILE THR GLN ASN MET PHE SEQRES 14 A 241 CYS ALA GLY TYR ASP THR LYS GLN GLU ASP ALA CYS GLN SEQRES 15 A 241 GLY ASP SER GLY GLY PRO HIS VAL THR ARG PHE LYS ASP SEQRES 16 A 241 THR TYR PHE VAL THR GLY ILE VAL SER TRP GLY GLU GLY SEQRES 17 A 241 CYS ALA ARG LYS GLY LYS TYR GLY ILE TYR THR LYS VAL SEQRES 18 A 241 THR ALA PHE LEU LYS TRP ILE ASP ARG SER MET LYS THR SEQRES 19 A 241 ARG GLY LEU PRO LYS ALA LYS SEQRES 1 L 55 ARG LYS LEU CYS SER LEU ASP ASN GLY ASP CYS ASP GLN SEQRES 2 L 55 PHE CYS HIS GLU GLU GLN ASN SER VAL VAL CYS SER CYS SEQRES 3 L 55 ALA ARG GLY TYR THR LEU ALA ASP ASN GLY LYS ALA CYS SEQRES 4 L 55 ILE PRO THR GLY PRO TYR PRO CYS GLY LYS GLN THR LEU SEQRES 5 L 55 GLU ARG ARG HET LZG A1245 33 HET CA A1246 1 HET NA A1247 1 HET NA A1248 1 HET NA A1249 1 HET CL A1250 1 HET CL A1251 1 HETNAM LZG 5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-4-FLUORO- HETNAM 2 LZG 1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)- HETNAM 3 LZG PHENYLCARBAMOYL]-METHYL}-PYRROLIDIN-3-YL)-AMIDE HETNAM CA CALCIUM ION HETNAM NA SODIUM ION HETNAM CL CHLORIDE ION FORMUL 3 LZG C22 H19 CL F2 N4 O3 S FORMUL 4 CA CA 2+ FORMUL 5 NA 3(NA 1+) FORMUL 8 CL 2(CL 1-) FORMUL 10 HOH *221(H2 O) HELIX 1 1 ALA A 55 ALA A 61A 5 8 HELIX 2 2 GLU A 124A LEU A 131A 1 9 HELIX 3 3 ASP A 164 SER A 172 1 9 HELIX 4 4 PHE A 234 MET A 242 1 9 HELIX 5 5 LEU L 91 CYS L 96 5 6 SHEET 1 AA 9 GLN A 20 GLU A 21 0 SHEET 2 AA 9 LYS A 156 VAL A 163 -1 O MET A 157 N GLN A 20 SHEET 3 AA 9 MET A 180 ALA A 183 -1 O CYS A 182 N VAL A 163 SHEET 4 AA 9 GLY A 226 LYS A 230 -1 O GLY A 226 N ALA A 183 SHEET 5 AA 9 THR A 206 TRP A 215 -1 O ILE A 212 N THR A 229 SHEET 6 AA 9 PRO A 198 PHE A 203 -1 O HIS A 199 N THR A 210 SHEET 7 AA 9 THR A 135 GLY A 140 -1 O ILE A 137 N VAL A 200 SHEET 8 AA 9 LYS A 156 VAL A 163 1 O LYS A 156 N GLY A 140 SHEET 9 AA 9 GLN A 20 GLU A 21 -1 O GLN A 20 N MET A 157 SHEET 1 AB 7 ALA A 81 HIS A 83 0 SHEET 2 AB 7 LYS A 65 VAL A 68 -1 O VAL A 66 N HIS A 83 SHEET 3 AB 7 GLN A 30 ILE A 34 -1 O LEU A 32 N ARG A 67 SHEET 4 AB 7 GLY A 40 ILE A 46 -1 N PHE A 41 O LEU A 33 SHEET 5 AB 7 TYR A 51 THR A 54 -1 O LEU A 53 N THR A 45 SHEET 6 AB 7 ALA A 104 LEU A 108 -1 O ALA A 104 N THR A 54 SHEET 7 AB 7 VAL A 85 LYS A 90 -1 N GLU A 86 O ARG A 107 SHEET 1 LA 2 TYR L 115 LEU L 117 0 SHEET 2 LA 2 CYS L 124 PRO L 126 -1 O ILE L 125 N THR L 116 SSBOND 1 CYS A 22 CYS A 27 1555 1555 2.05 SSBOND 2 CYS A 42 CYS A 58 1555 1555 2.08 SSBOND 3 CYS A 122 CYS L 132 1555 1555 2.03 SSBOND 4 CYS A 168 CYS A 182 1555 1555 2.03 SSBOND 5 CYS A 191 CYS A 220 1555 1555 2.05 SSBOND 6 CYS L 89 CYS L 100 1555 1555 2.03 SSBOND 7 CYS L 96 CYS L 109 1555 1555 2.04 SSBOND 8 CYS L 111 CYS L 124 1555 1555 2.03 LINK OE1 GLN A 20 NA NA A1249 8665 1555 2.27 LINK OE1 GLN A 20 NA NA A1249 1555 1555 2.30 LINK OD1 ASP A 70 CA CA A1246 1555 1555 2.26 LINK O ASN A 72 CA CA A1246 1555 1555 2.26 LINK O GLN A 75 CA CA A1246 1555 1555 2.26 LINK OE2 GLU A 77 CA CA A1246 1555 1555 2.31 LINK OE2 GLU A 80 CA CA A1246 1555 1555 2.28 LINK O TYR A 185 NA NA A1247 1555 1555 2.28 LINK O ASP A 185A NA NA A1247 1555 1555 2.50 LINK O ARG A 222 NA NA A1247 1555 1555 2.27 LINK CA CA A1246 O HOH A2060 1555 1555 2.02 LINK NA NA A1247 O HOH A2163 1555 1555 2.40 LINK NA NA A1248 O HOH A2038 1555 1555 2.06 LINK NA NA A1248 O HOH A2039 1555 1555 2.15 LINK NA NA A1248 O HOH A2103 1555 1555 2.31 LINK NA NA A1248 O HOH A2105 1555 1555 1.95 LINK NA NA A1248 O HOH A2106 1555 1555 2.11 LINK NA NA A1248 O HOH A2131 1555 1555 2.22 LINK NA NA A1249 O HOH A2010 1555 8665 2.24 LINK NA NA A1249 O HOH A2010 1555 1555 2.26 LINK NA NA A1249 O HOH A2011 1555 8665 2.00 LINK NA NA A1249 O HOH A2011 1555 1555 2.00 SITE 1 AC1 23 GLU A 97 THR A 98 TYR A 99 ASN A 166 SITE 2 AC1 23 LYS A 169 PHE A 174 ASP A 189 ALA A 190 SITE 3 AC1 23 GLN A 192 VAL A 213 TRP A 215 GLY A 216 SITE 4 AC1 23 GLY A 218 CYS A 220 GLY A 226 ILE A 227 SITE 5 AC1 23 TYR A 228 CL A1250 HOH A2141 HOH A2143 SITE 6 AC1 23 HOH A2172 HOH A2208 HOH A2209 SITE 1 AC2 6 ASP A 70 ASN A 72 GLN A 75 GLU A 77 SITE 2 AC2 6 GLU A 80 HOH A2060 SITE 1 AC3 6 TYR A 185 ASP A 185A ARG A 222 LYS A 224 SITE 2 AC3 6 HOH A2163 HOH A2188 SITE 1 AC4 6 HOH A2038 HOH A2039 HOH A2103 HOH A2105 SITE 2 AC4 6 HOH A2106 HOH A2131 SITE 1 AC5 3 GLN A 20 HOH A2010 HOH A2011 SITE 1 AC6 4 ASN A 166 GLY A 218 LZG A1245 HOH A2184 SITE 1 AC7 4 GLN A 61 LYS A 96 THR A 177 GLN A 178 CRYST1 105.281 105.281 49.405 90.00 90.00 90.00 P 43 21 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.009498 0.000000 0.000000 0.00000 SCALE2 0.000000 0.009498 0.000000 0.00000 SCALE3 0.000000 0.000000 0.020241 0.00000